Iron Metabolism Disorders  >>  Monofer (iron isomaltoside 1000)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Monofer (iron isomaltoside 1000) / Pharmacosmos
NCT00536666 / 2007-000765-37: A Study of Iron Oligosaccharide in Chronic Kidney Disease Patients

Completed
3
182
Europe
Iron oligosaccharide, MonoFer
Pharmacosmos A/S
Chronic Kidney Disease, Anemia, Iron-Deficiency
08/08
08/08
NCT01017614 / 2009-012544-16: Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia

Completed
3
350
Europe, RoW
Monofer, Iron Sulphate
Pharmacosmos A/S, Max Neeman International
Inflammatory Bowel Disease
07/12
08/12
NCT01102413 / 2009-016728-29: Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia

Completed
3
351
Europe
Monofer, Iron Sulphate
Pharmacosmos A/S
Iron Deficiency Anemia, Chronic Kidney Disease
06/14
06/14
NCT02172001 / 2014-001518-25: A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo

Withdrawn
3
0
US
Iron isomaltoside 1000, Natrium Chloride 0,9%
Pharmacosmos A/S
Iron Deficiency Anemia
03/15
 
NCT02130063: IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose

Completed
3
511
US
iron isomaltoside 1000 (Monofer®), iron sucrose (Venofer®)
Pharmacosmos A/S, BioStata, ClinStar, LLC, Laboratory Corporation of America
Iron Deficiency Anaemia
08/15
08/15
NCT01895231 / 2012-001529-28: A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-deficient Blood Donors

Completed
3
107
Europe
Iron isomaltoside 1000 (Monofer®), Monofer®, Placebo, 0.9 % saline
Pharmacosmos A/S, Max Neeman
Iron-deficiency
12/16
12/16

Download Options